Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 11/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21606455 | 0.90 | GABRA2 (0.40) | GABRA2GABRB2OPRK1GABRG2GABRB3 | |
| SCHEMBL21598069 | 0.88 | RXFP1 (0.36) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL21598049 | 0.83 | GABRA2 (0.52) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21606397 | 0.83 | NOTUM (0.47) | GABRA2GABRB2OPRK1GABRG2GABRB3 | |
| SCHEMBL21606347 | 0.77 | GABRA2 (0.42) | GABRA2GABRB2OPRK1GABRG2GABRB3 | |
| SCHEMBL21598060 | 0.77 | RORC (0.45) | OPRK1L3MBTL1ALDH1A1 | |
| SCHEMBL31309319 | 0.76 | RXFP1 (0.45) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21606484 | 0.75 | GABRA2 (0.48) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21606471 | 0.74 | GABRA2 (0.44) | GABRA2GABRB2OPRK1GABRG2GABRB3 | |
| SCHEMBL21606475 | 0.74 | RORC (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| WO-2019244000-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | RORC, RORB, RORA | GABRA2 1154/4885GABRB2 984/4885OPRK1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.